SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Cost-Effectiveness of Adding Rh-Endostatin to First-Line Chemotherapy in Patients With Advanced Non-Small-Cell Lung Cancer in China
10 references·0 citing·49 second hop
Cost-Effectiveness of Adding Rh-Endostatin to First-Line Chemotherapy in Patients With Advanced Non-Small-Cell Lung Cancer in China (2011)Cost-Effectiveness of Adding Rh-Endostati…China's primary health-care reform (2011)China's primary health-care r…How Much Is Life Worth: Cetuximab, Non-Small Cell Lung Cancer, and the $440 Billion Question (2009)How Much Is Life Worth: Cetux…The Potential Clinical and Economic Outcomes of Pharmacogenomic Approaches to EGFR-Tyrosine Kinase Inhibitor Therapy in Non–Small-Cell Lung Cancer (2008)The Potential Clinical and Ec…Probabilistic Analysis of Cost-Effectiveness Models: Statistical Representation of Parameter Uncertainty (2005)Probabilistic Analysis of Cos…How Sensitive Are Cost-Effectiveness Analyses to Choice of Parametric Distributions? (2005)How Sensitive Are Cost-Effect…Use of Cost-Effectiveness Analysis in Health-Care Resource Allocation Decision-Making: How Are Cost-Effectiveness Thresholds Expected to Emerge? (2004)Use of Cost-Effectiveness Ana…Modelling in the economic evaluation of health care: selecting the appropriate approach (2004)Modelling in the economic eva…Modelling in Health Economic Evaluation (2000)Modelling in Health Economic …Problems of using modelling in the economic evaluation of health care (1996)Problems of using modelling i…Probabilistic Sensitivity Analysis Using Monte Carlo Simulation (1985)Probabilistic Sensitivity Ana…Decision Analysis: Introductory Lectures on Choices Under Uncertainty. (1969)Judgment under Uncertainty: Heuristics and Biases (1974)Clinical Decision Analysis (1980)Handling Uncertainty in Cost-Effectiveness Models (2000)Review of guidelines for good practice in decision-analytic modelling in health technology assessment (2004)The Cost-Effectiveness of Lifestyle Modification or Metformin in Preventing Type 2 Diabetes in Adults with Impaired Glucose Tolerance (2005)The scandal of poor medical research (1994)Uncertainty in the economic evaluation of health care technologies: The role of sensitivity analysis (1994)Misleading meta-analysis (1995)Assessing the costs of healthcare technologies in clinical trials. (1999)Testing the Validity of Cost-Effectiveness Models (2000)The cost-effectiveness of magnetic resonance angiography for carotid artery stenosis and peripheral vascular disease: a systematic review (2002)How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. (1992)Cost-Effectiveness in Health and Medicine (1996)Recommendations of the Panel on Cost-Effectiveness in Health and Medicine (1996)Bias in published cost effectiveness studies: systematic review (2006)Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold (2008)What Does the Value of Modern Medicine Say About the $50,000 per Quality-Adjusted Life-Year Decision Rule? (2008)Markov Models in Medical Decision Making (1993)An Introduction to Markov Modelling for Economic Evaluation (1998)The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies (1999)Pharmacoeconomic Analyses Using Discrete Event Simulation (2005)Economic evaluation using decision analytical modelling: design, conduct, analysis, and reporting (2011)Conceptualizing a Model: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-2 (2012)Net Health Benefits (1998)How should cost data in pragmatic randomised trials be analysed? (2000)Addressing the issues that arise in analysing multicentre cost data, with application to a multinational study (2006)Statistical Methods for Cost-Effectiveness Analyses That Use Data from Cluster Randomized Trials (2011)The statistical approach in trial-based economic evaluations matters: get your statistics together! (2021)Modelling in Ecomomic Evaluation: An Unavoidable Fact of Life (1997)A rational framework for decision making by the National Institute For Clinical Excellence (NICE) (2002)Economic Evaluation of Sunitinib Malate for the First-Line Treatment of Metastatic Renal Cell Carcinoma (2008)Sensitivity analysis in economic evaluation: an audit of NICE current practice and a review of its use and value in decision-making (2009)Uncertainty and Patient Heterogeneity in Medical Decision Models (2010)Cost of care for cancer in a health maintenance organization. (1997)Decision Modelling For Health Economic Evaluation (2006)Economic Analysis: Randomized Placebo-Controlled Clinical Trial of Erlotinib in Advanced Non-Small Cell Lung Cancer (2010)A Systematic and Critical Review of the Evolving Methods and Applications of Value of Information in Academia and Practice (2012)Is Individualized Medicine More Cost-Effective? A Systematic Review (2014)An economic approach to clinical trial design and research priority-setting (1996)Transferability of economic evaluations: approaches and factors to consider when using results from one geographic area for another (2007)Assessing the value of screening tools: reviewing the challenges and opportunities of cost-effectiveness analysis (2018)Cost-effectiveness analyses of genetic and genomic diagnostic tests (2018)Efficiency and productivity measurement of rural township hospitals in China: a bootstrapping data envelopment analysis (2016)Does health insurance reduce out-of-pocket expenditure? Heterogeneity among China's middle-aged and elderly (2017)Prevalence of Workplace Violence Against Health-Care Professionals in China: A Comprehensive Meta-Analysis of Observational Surveys (2018)When is Cancer Care Cost-Effective? A Systematic Overview of Cost–Utility Analyses in Oncology (2010)Essential Epidemiology: An Introduction for Students and Health Professionals (2012)Cancer Drugs in the United States: Justum Pretium—The Just Price (2013)
this work references cited by second hop

References

  • 1985Probabilistic Sensitivity Analysis Using Monte Carlo Simulation860 cited
  • 2004Use of Cost-Effectiveness Analysis in Health-Care Resource Allocation Decision-Making: How Are Cost-Effectiveness Thresholds Expected to Emerge?790 cited
  • 2009How Much Is Life Worth: Cetuximab, Non-Small Cell Lung Cancer, and the $440 Billion Question351 cited
  • 2004Modelling in the economic evaluation of health care: selecting the appropriate approach291 cited
  • 2005Probabilistic Analysis of Cost-Effectiveness Models: Statistical Representation of Parameter Uncertainty185 cited
  • 2000Modelling in Health Economic Evaluation165 cited
  • 1996Problems of using modelling in the economic evaluation of health care163 cited
  • 2011China's primary health-care reform150 cited
  • 2008The Potential Clinical and Economic Outcomes of Pharmacogenomic Approaches to EGFR-Tyrosine Kinase Inhibitor Therapy in Non–Small-Cell Lung Cancer86 cited
  • 2005How Sensitive Are Cost-Effectiveness Analyses to Choice of Parametric Distributions?80 cited

Cited by

No citing works inside the corpus for this window.

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work